APA. V. Privalov

A. V. Privalov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. V. Privalov has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Application of artificial intelligence in assessing the size of colon tumors during endoscopic examination

    by K. I. Kulaev, A. V. Vazhenin, A. V. Privalov, E. A. Pushkarev, K. S. Zuykov, I. A. Popova, V. E. Samarkin, E. V. Alkhanov, D. M. Kutuzov, A. I. Kulaev, et al.

    Introduction. The risk of malignancy of precancerous colonic lesions directly depends on the size of the neoplasms detected during colonoscopy. According to various authors, neoplasms up to 2.0 cm in diameter have a 12.5% risk of harboring malignant cells. If the neoplasm is larger than 2.0 cm, the risk of malignancy increases significantly and, according to various authors, ranges from 31 to 57%. The endoscopist’s subjective assessment of neoplasm size often does not correspond to the actual size, leading to inappropriate treatment decisions. Aim. To develop and evaluate the effectiveness of a hardware-based subsystem for measuring the size of colonic neoplasms (AI-assisted neoplasm size estimation, AIANSE) during colonoscopy with AI-assisted colonoscopy detection (AIAC). Materials and methods. From 2022 to 2024, the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, in collaboration with the Russian company EVA Lab, developed and implemented a clinical decision support system based on artificial intelligence algorithms. The study included 1,763 patients, from whom approximately 27,000 frames were labeled. Results. Computer processing of endoscopic images demonstrated its effectiveness in both tumor detection and tumor size estimation. This is confirmed by comparing colonoscopy image analysis data with the actual dimensions of the neoplasms determined after surgical treatment. The system possesses self-learning capabilities, as evidenced by the increase in specificity (from 63% to 70%), sensitivity (from 64% to 70%), and accuracy (from 66% to 71%) between 2022 and 2024. Conclusions. AIANSE, a computer-based tumor analysis and size measurement system, was developed for the first time. This system demonstrated its effectiveness in tumor size estimation, with an accuracy of 71%. This development demonstrated its greatest effectiveness in measuring tumor sizes of 5 mm in diameter, with an accuracy of 76%.

  • Open Access

    Консенсус по лечению больных псевдомиксомой брюшины

    by А. Е. Калинин, В. Гущин, А. А. Доманский, О. А. Кузнецова, В. А. Шаленков, С. А. Абудеев, Н. А. Козлов, В. А. Колышкин, А. В. Привалов, Е. Г. Рыбаков, et al.

    Введение: Лечение больных псевдомиксомой брюшины — одна из сложных и нерешенных проблем в онкологии. В отечественной медицинской литературе тема псевдомиксомы брюшины представлена единичными разрозненными публикациями. В основных зарубежных национальных клинических руководствах данная тема также не освещена. Основными документами, определяющими подходы к лечению псевдомиксомы брюшины, являются национальные консенсусы. Настоящий Консенсус является первой попыткой предложить стандартизованные подходы к проблеме псевдомиксомы брюшины в России.Методы: Настоящий Консенсус принят на основании анализа литературных данных, анализа известных зарубежных консенсусов, а также в результате серии обсуждений с участием специалистов, имеющих значительный личный опыт в диагностике и лечении псевдомиксомы брюшины.Результаты: Итоговый документ Консенсуса представлен в формате расширенных клинических рекомендаций, освещающих все аспекты данной патологии — эпидемиологию, патогенез, классификацию, клиническую картину, диагностику, и возможные варианты лечения, наблюдение после лечения и организационные вопросы.Заключение: Настоящий Консенсус создан с целью предложить практикующим врачам оптимальную стратегию лечения псевдомиксомы брюшины, а также информировать врачей (как онкологов, так и общего профиля) об особенностях данной редкой патологии.

  • A retrospective cohort study of the effect of zolendronic acid on mandibular bone optical density in cancer patients

    by I.G. Shelegova, N.S. Nurieva, M.A. Izosimova, A.V. Privalov

    The aim the study. To analyze the density of the mandible in cancer patients during treatment with zoledronic acid. Materials and methods. A retrospective cohort study included 45 patients with cancer aged 26—81 years (average age 55±12.88 years), of whom 14 patients had bone metastases (n=14) and took 4 mg of zolendronic acid once every 28 days. The patients underwent standard PET-CT examinations in the «whole body» mode, and the density of the mandible was examined on CT. Radiation therapy was performed by intracavitary administration of strontium 89 chloride; remote radiation therapy with cisplatin radiomodification. In the presence of bone metastases, patients received complex supportive therapy with zolendronic acid. The effect of zolendronic acid on the density of the mandible in the frontal and lateral sections was studied by multidimensional dispersion analysis. Results. Statistically significant differences (p=0.002) were revealed for density indicators according to CT scans of the mandible in the frontal region against the background of zolendronic acid therapy. We attribute the absence of statistically significant differences for the density of the mandible in the lateral sections (p=0.101 and p=0.082) against the background of zolendronic acid therapy to a measurement bias. We attribute the absence of statistically significant differences in density indices against the background of hormonal, radiation, targeted and chemotherapy to the design of the study. Conclusion. Density measurement based on CT examination data can be recommended for use as an additional tool in assessing the effect of zolendronic acid on the density of the mandible. However, the method of measuring the density of the mandible in the lateral sections requires improvement to prevent measurement bias.

  • Undifferentiated pancreatic carcinoma with osteoclast-like giant cells

    by A.YU. Shamanova, D.M. Rostovtsev, A.V. Privalov, L.V. Yarina, K.S. Aristarkhova, G.V. Sychugov, I.V. Vasil’kOva, A.S. Artem’eVa, V.V. Saevets, E.A. Alymov

    In the structure of malignant oncological diseases of the Russian population, pancreatic cancer (PCa) occupies the 10th place with a high mortality rate in case of late diagnosis, which is primarily due to the minimal clinical manifestations of this pathology and the absence of precancer as a potential substrate for screening. Undifferentiated pancreatic carcinoma with osteoclast-like giant cell (UC-OGC) is a rare histological variant of PCa with discussed bidirectional histogenesis (epithelial and mesenchymal), epithelial-mesenchymal transition in the tumor and variable prognosis depending on the predominant cellular component. A review of the literature reflecting debatable issues of origin, clinical and pathological characteristics and prognosis of UC-OGC, as well as a description of a clinical case is relevant due to the rare occurrence of this tumor in the routine work of pathologists and oncologists.


  • Open Access

    Role of hyperthermic intraperitoneal chemotherapy in combination with an intraperitoneal port system in the treatment of patients with advanced ovarian cancer

    by V. V. Saevets, A. V. Privalov, A. V. Vazhenin, A. Yu. Shamanova, A. A. Mukhin, A. V. Taratonov, Yu. A. Semenov, T. N. Shamaeva

    Background. The survival rate of patients with ovarian malignancies depends on the prevalence of the tumor process, the volume of surgical treatment, and the size of the residual tumor. At the first stage, an «aggressive» surgical tactic of removing all macroscopically determined tumor foci with subsequent antitumor drug therapy is recommended. However, the results of treatment remain unsatisfactory, which dictates the need to search for new methods of treatment.Objective: to evaluate the effectiveness of implantable port systems for intraperitoneal chemotherapy administration in the treatment of patients with advanced stages of ovarian cancer.Materials and methods. 37 cases of stage IIIC ovarian cancer were studied for the period 2018–2019. At the first stage of treatment, a cytoreductive operation was performed. At the second stage, the patients were randomly randomized into three groups: group 1 (n = 9) – installation of a port system + hyperthermic intraperitoneal chemoperfusion followed by intraperitoneal chemotherapy; group 2 (n = 11) – hyperthermic intraperitoneal chemoperfusion followed by systemic intravenous chemotherapy; group 3 (n = 17) – control group, intravenous administration of antitumor drugs. The observation period is 27 months. In the study groups, the indicators of age distribution, the degree of malignancy of the neoplasm, the volume of the residual tumor, and the relapse-free survival were analyzed.Results. Trends towards differences in progression-free survival were found in all study groups. In group 1, there was no relapse in all patients. In group 2, relapses amounted to 18.2 %, in group 3–23.5 %. G3 ovarian cancer (6 (66.7 %) and 6 (54.5 %) cases, respectively) prevailed in groups 1 and 2; G1 ovarian cancer (9 (52.9 %) cases) prevailed in group 3. Discussion. Features of the chemical composition and method of administration of the drug increase the effectiveness of local exposure to tumor cells. The introduction of cytostatic agents into the abdominal cavity leads to minimal systemic toxicity, which exceeds the results of standard intravenous therapy.Conclusion. An advantage in the relapse-free survival of patients after hyperthermic intraperitoneal chemoperfusion in combination with an implantable port system was found in comparison with standard methods of treatment.


  • Open Access

    Treatment of advanced-stage ovarian cancer including combination of intra-abdominal chemotherapy

    by V. V. Saevets, A. V. Privalov, A. V. Vazhenin, Y. A. Semenov, A. V. Shmidt

    Introduction.Ovarian cancer is the leading cause of death from gynecological malignancies: the one-year relative survival rate with stages 3 and 4 of the disease is 20%. The results of treatment remain unsatisfactory, which dictates the need to find new methods of treatment. The aim of the study was to evaluate the effectiveness of the use of HIIH (hyperthermic intraperitoneal intraoperative chemoperfusion, HIPEC) in patients with the diagnosis of: ovarian cancer IIIA-From the stage of the disease.Materials and methods.117 cases of stage IIIA-C ovarian cancer treated at the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine from January 2014 to March 2021 were retrospectively studied. All patients underwent 3 cycles of neoadjuvant chemotherapy (NAPHT) according to the paclitaxel+carboplatin (PCb) scheme, followed by surgical treatment to the extent of maximum cytoreductive surgery. Two study groups were formed: 1 — cases with GIIH (N=57), 2-without GIIH (N=60). On the 14-16 day after the operation, all patients underwent 3 cycles of adjuvant chemotherapy according to the PCb scheme.Results.A significant increase in overall survival was found in the first group of patients with HIPEC. This technique allows to increase the survival rate of patients for 14 months at stage IIIA-B (p0.05), which is associated with the pronounced prevalence of the tumor process and the technical impossibility of removing the tumor. Discussion.The concentration of drugs in the abdominal cavity and in the blood plasma significantly differs due to the functioning of the peritoneal-plasma barrier, which leads to a lower toxicity in comparison with systemic chemotherapy, and therefore allows you to give a large dose of the drug with fewer adverse events, and the fact of hyperthermia (42°C) has a positive effect on the effectiveness of intraperitoneal chemotherapy. To date, this method has not been included in the clinical recommendations on the territory of the Russian Federation, but data from foreign literature, including randomized trials, have shown the high effectiveness of this method.Conclusion.The results obtained in the course of our study demonstrate the effectiveness of this technique, in the form of an increase in overall and relapse-free survival with acceptable toxicity.


  • Open Access

    Evaluation of the efficiency of perioperative chemotherapy in the complex treatment of gastric cancer

    by Е. О. Mantsyrev, A. V. Privalov, S. V. Kuvaev, К. V. Semikopov, I. A. Gavrishkin

    Introduction.Of greatest interest in the complex treatment of gastric cancer is the assessment of the effect of perioperative chemotherapy on the immediate and long-term results of treatment. Including, the possibility of studying the effectiveness of chemotherapy, its effect on the resectability of the tumor process, determining the possibility of an indirect correlation for intra — and postoperative complications.The aim of the studyis to study the effectiveness of perioperative chemotherapy in the treatment of gastric cancer and its direct effect on the results of surgical treatment.Methods.At the base Chelyabinsk Center of Oncology and Nuclear Medicine, studies are being conducted to assess the effectiveness and tolerability of perioperative chemotherapy in the complex treatment of gastric cancer. Based on the inclusion criteria, 80 patients were selected with a diagnosis of gastric cancer T2-3N0-2M0. The first stage of all patients underwent diagnostic laparoscopy with negative peritoneal washings. The male to female ratio was 51% and 49%, respectively. The average age of the patients was 61 years. By morphological structure, gastric adenocarcinoma prevailed — 85%, cricoid cell carcinoma was 9%, adenocarcinoma with a cricoid cell component — 6%. According to the T category, the patients were distributed as follows: cT2 — 5%; sT3 — 59%; cT4 — 36%. In category N, patients of category N1 prevailed — 59%; patients with cN0 and cN1 were represented in approximately equal proportions, 14% and 19%, respectively. Patients with stage II accounted for 33%, with stage III — 67%. The main combination of drugs was FLOT (87%), FolFox (3%), XELOX (5%), PF (5%) were also used.Results. The data obtained clearly demonstrate the good tolerability of the performed preoperative chemotherapy, the absence of significant adverse reactions. Drug therapy did not affect the planned timing of the surgical stage of treatment. Also, no effect of chemotherapy on postoperative complications was noted. R0 resection was performed in 100% of cases. In 49% of cases, stage reduction was performed. Significant medical grade III — IV pathomorphosis was obtained in 26% of cases. Discussion.Interpretation of therapeutic tumor pathomorphosis for evaluating the effectiveness and planning of adjuvant therapy currently requires further study and evaluation.Conclusion.Perioperative chemotherapy is not accompanied by adverse reactions affecting the timing and outcome of treatment. The obtained positive clinical effect according to examination data, intraoperative visual assessment suggests an improvement in overall survival and a decrease in one-year mortality in the complex treatment of gastric cancer.